Anti 2019-nCoV Spike Protein  Neutralizing Nanobody (NBX20014)(C19S1-644HL)

Anti 2019-nCoV Spike Protein Neutralizing Nanobody (NBX20014)(C19S1-644HL)

  • $165.00


FOR BULK ORDER REQUESTS PLEASE CONTACT US

Description: Recombinant Llama VHH-Human IgG Antibody

Specificity: Recognizes the 2019-nCoV Spike protein.  Neutralizing activity validated for wild type Spike protein RBD and Spike protein RBD (N501Y) variant

Cited Applications: ELISA. For studying neutralization SARS-CoV-2 spike protein detection assays. Ideal working dilutions for each application should be empirically determined by the investigator.

Host / Isotype / Clone# : Llama VHH-Human IgG Fc

Stability:1yr at –20oC from date of shipment.

Scientific Background: The severe acute respiratory syndrome-related novel coronavirus SARS-CoV-2 has caused the pandemic of respiratory diseases (COVID-19) around the world in 2020 (1). The spike glycoprotein (S) of coronavirus belongs to the type I transmembrane protein containing two subunits, S1 and S2 (2), which is also known to be the key component to bind with host cells through the interaction with angiotensin-converting enzyme 2 (ACE2) (3). A receptor-binding domain (RBD) of S1 can recognize the cell surface receptor and the mutation of RBD could cause a higher motility rate (3).

References:

1. Zhou P, et al: A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020, 579:270-89.

2. Xiao X, et al: The SARS-CoV S glycoprotein. Cell Mol Life Sci. 2004, 61 (19-20): 2428-30.

3. Lan J, et al: Crystal structure of the 2019-nCov spike receptor-binding domain bound with the ACE2 receptor. bioRxiv. doi: https://doi.org/10.1101/2020.02.19.956235

Assay Data: Sample assay data. for lot-specific data, please refer to the specific datasheet. 

Assay Data: Sample assay data. for lot-specific data, please refer to the specific datasheet. 

Product Sheets (By Lot #) :

F4035-18.pdf